Evidence map›Paper›PMID 33251993›Full record

ArticleJournal of managed care & specialty pharmacy2020

A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.

Dana McCormick, Deepak L Bhatt, Harold E Bays, Pam R Taub, Kim A Caldwell, Chris K Guerin, Jeff Steinhoff, Zahid Ahmad, Rubina Singh, Kathleen Moreo and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Dana McCormickBlue Cross Blue Shield of Texas, Richardson, TX.
Deepak L BhattBrigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA.
Harold E BaysLouisville Metabolic and Atherosclerosis Research Center, Louisville, KY.
Pam R TaubDivision of Cardiovascular Medicine, University of California San Diego School of Medicine.
Kim A CaldwellTexas Star Healthcare Consulting, McKinney.
Chris K GuerinTri-City Medical Center and University of California San Diego School of Medicine.
Jeff SteinhoffLargo Medical Center, Largo, FL; HCA Healthcare/USF Morsani College of Medicine, Tampa, FL; and Nova Southeastern University, Davie, FL.
Zahid AhmadDivision of Nutrition and Metabolic Disease, UT Southwestern Medical Center, Dallas, TX.
Rubina SinghAMCP, Alexandria, VA.
Kathleen MoreoPRIME Education, Fort Lauderdale, FL.
Jeffrey CarterPRIME Education, Fort Lauderdale, FL.
Cherilyn L HeggenPRIME Education, Fort Lauderdale, FL.
Tamar SapirPRIME Education, Fort Lauderdale, FL.
Blue Cross and Blue Shield of Kansas City · USHarvard University · USLouisville Metabolic and Atherosclerosis Research Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PCSK9 InhibitorsAnticholesteremic AgentsAtherosclerosisCardiovascular DiseasesCost-Benefit AnalysisDocumentationDrug CostsFocus GroupsHumansHyperlipoproteinemia Type IIMedication AdherenceProprotein Convertase 9Quality of Health CareSurveys and QuestionnairesTreatment OutcomeUnited StatesAnticholesteremic AgentsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Identifiers

PMID33251993
PMCPMC10391214
OpenAlexW3109806833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.